Talphera TLPH
NASDAQ TLPH
$1.24 +0.02 (+1.64%)
At close: Sep 10, 2026 · 4:00 PM EDT

Talphera (TLPH) Non-Current Deffered Revenue (2010 - 2022)

Talphera (TLPH) posted Non-Current Deffered Revenue of $1.0 million for Q4 2022, down 2.63% on a QoQ basis from $1.1 million in Q3 2022, and down 9.99% year-over-year from $1.2 million in Q4 2021.

Analysis

Talphera (TLPH) Non-Current Deffered Revenue (2010 - 2022) Analysis & Trends

Talphera has reported Non-Current Deffered Revenue for 13 years, with the latest figure at $1.0 million in Q4 2022.

  • On a quarterly basis, Non-Current Deffered Revenue fell 9.99% year-over-year to $1.0 million in Q4 2022; TTM through Dec 2022 was $1.0 million, a 9.99% decrease from a year earlier, with the FY2022 full-year figure at $1.0 million, down 9.99% from the prior year.
  • Non-Current Deffered Revenue was $1.0 million for Q4 2022 at Talphera, down from $1.1 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $3.4 million in Q1 2018, with the low at $1.0 million in Q4 2022.
  • Average Non-Current Deffered Revenue over 5 years is $2.3 million, with a median of $2.8 million recorded in 2019.
  • The sharpest annual moves came in 2018 and 2022: Non-Current Deffered Revenue retreated 9.1% in 2018, then dropped 13.99% in 2022.
  • Over 5 years, Non-Current Deffered Revenue stood at $3.1 million in 2018, then retreated by 10.01% to $2.8 million in 2019, then retreated by 2.79% to $2.8 million in 2020, then plunged by 58.21% to $1.2 million in 2021, then retreated by 9.99% to $1.0 million in 2022.
  • The last three Non-Current Deffered Revenue figures came in at $1.0 million (Q4 2022), $1.1 million (Q3 2022), and $1.1 million (Q2 2022), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn -
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 220.40 Mn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 147.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn -
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Talphera 92.90 Mn 92.90 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 1.04 Mn
Sep 30, 2022 1.06 Mn
Jun 30, 2022 1.09 Mn
Mar 31, 2022 1.12 Mn
Dec 31, 2021 1.15 Mn
Sep 30, 2021 1.24 Mn
Mar 31, 2020 2.75 Mn
Dec 31, 2019 2.83 Mn
Sep 30, 2019 2.91 Mn
Jun 30, 2019 2.99 Mn
Mar 31, 2019 3.07 Mn
Dec 31, 2018 3.15 Mn
Sep 30, 2018 3.23 Mn
Jun 30, 2018 3.31 Mn
Mar 31, 2018 3.38 Mn
Dec 31, 2017 3.46 Mn
Sep 30, 2017 3.55 Mn
Jun 30, 2017 3.64 Mn
Mar 31, 2017 3.73 Mn
Dec 31, 2016 3.82 Mn